BrainSTIM: Brain State-dependent Stimulation to Improve Movement

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05103176
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
65
1
3
16.5
3.9

Study Details

Study Description

Brief Summary

Repetitive transcranial magnetic stimulation (rTMS) is a powerful tool to non-invasively modulate brain circuits, brain plasticity, and behavior. This proposal will test the hypothesis that controlling behavioral state during focal multi-day rTMS of a brain region involved in grasping movements will enhance the functional specificity of the neuromodulation action among distributed brain regions involved in voluntary motor control and concomitantly improve manual dexterity. Results from this study will be used to optimize rTMS therapy for individuals with neuromotor impairments by controlling behavioral state to improve the efficacy of rTMS treatment.

Healthy volunteers that qualify for this study will have motor skill assessments and basic neuromotor testing (using neurophysiology with TMS and functional Magnetic Resonance Imaging (fMRI) scans). Participants will be asked to come in for up to nine sessions that include 1 screening session, 5 consecutive daily rTMS sessions and 3 assessment sessions with resting-state and task-based fMRI, neurophysiology with TMS, and hand motor tasks over the course of 3-4 weeks.

Condition or Disease Intervention/Treatment Phase
  • Device: TMS
  • Behavioral: Object directed grasping
N/A

Detailed Description

This study will examine a particular type of rTMS, known as theta burst stimulation (TBS), which has been shown to induce longer lasting effects than other forms of rTMS, making TBS an important tool for therapeutic applications. While TBS provides relatively focal stimulation, effects on the brain occur through interconnected networks in ways that are poorly understood. Moreover, stimulation is highly state-dependent, and the use of rTMS in most therapeutic settings, such as the treatment of motor impairments, leaves behavioral state uncontrolled. Augmenting rTMS therapy by inducing specific behavioral states is an attractive idea for improving therapeutic rTMS, but the relevant knowledge base is sparse. To address this critical gap, this exploratory R21 proposal will examine the effects of TBS and behavioral state on brain and motor behavior. The investigators will test the broad hypothesis that when TBS is applied during a controlled behavior state, motor function will be facilitated, compared to stimulation when behavioral state is uncontrolled. The investigators will focus on the posterior parietal cortex (PPC), and associated parietofrontal circuits, which subserve skilled grasp control, an ability known to be impaired in stroke, traumatic brain injury, and other motor disorders. The investigators will collect functional magnetic resonance imaging (fMRI), neurophysiological measures with TMS, and behavioral measures in all subjects for three different interventions.

In Aim 1, the investigators will show improvement in action performance by manipulating the behavioral state during PPC stimulation.

In Aim 2, the investigators will demonstrate modulation of neurophysiological aftereffects of PPC stimulation on motor output by manipulating behavioral state.

In Aim 3, the investigators will assess the relationship between brain connectivity, plasticity and behavior in response to the behavioral state during brain stimulation.

Impact: Results will provide insights into the effects of rTMS and behavioral state on the brain and behavior. This knowledge will lay a mechanistic foundation for future studies to show how controlling behavioral state during rTMS can improve therapeutic efficacy in neurological disorders.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
65 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The investigators will use a randomized block design with up to 65 subjects in up to nine sessions. The first session will screen subjects before enrolling subjects into study. Three sessions will collect functional magnetic resonance imaging (fMRI) scans, neurophysiological measures with TMS, and behavioral measures. After a baseline testing session, subsequent sessions over five days will entail rTMS, followed by two assessments to evaluate the effects of stimulation on brain and behavior. rTMS intervention sessions will consist of: (i) Posterior Parietal Cortex (PPC) stimulation alone, (ii) PPC stimulation paired with a grasp task or (iii) vertex stimulation (as a control condition) paired with a grasp task. Duration of study: Approximately 3-4 weeks (depending upon scheduling)The investigators will use a randomized block design with up to 65 subjects in up to nine sessions. The first session will screen subjects before enrolling subjects into study. Three sessions will collect functional magnetic resonance imaging (fMRI) scans, neurophysiological measures with TMS, and behavioral measures. After a baseline testing session, subsequent sessions over five days will entail rTMS, followed by two assessments to evaluate the effects of stimulation on brain and behavior. rTMS intervention sessions will consist of: (i) Posterior Parietal Cortex (PPC) stimulation alone, (ii) PPC stimulation paired with a grasp task or (iii) vertex stimulation (as a control condition) paired with a grasp task. Duration of study: Approximately 3-4 weeks (depending upon scheduling)
Masking:
Single (Participant)
Masking Description:
Subjects will be randomly assigned to one of the 3 arms of the study. Subjects will be blind to which arm they are in, however, will be aware of what is involved within each of the arms.
Primary Purpose:
Basic Science
Official Title:
Leveraging Behavioral State to Enhance Specificity of Non-invasive Brain Stimulation on Motor Circuits
Actual Study Start Date :
Feb 15, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: To PPC, with concurrent task

This arm will receive intermittent theta bust stimulation to the PPC site while subjects perform a grasp task

Device: TMS
A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
Other Names:
  • MagPro X100 TMS system
  • Behavioral: Object directed grasping
    Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After ~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every "GO" cue in order to modulate cortical activity during both the planning and execution phase of the action.

    Experimental: To PPC, without a concurrent task

    This arm will receive intermittent theta bust stimulation to the PPC site without a concurrent task

    Device: TMS
    A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
    Other Names:
  • MagPro X100 TMS system
  • Experimental: To vertex, with concurrent task

    This arm will receive intermittent theta bust stimulation to the vertex site (control condition) while subjects perform a grasp task

    Device: TMS
    A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
    Other Names:
  • MagPro X100 TMS system
  • Behavioral: Object directed grasping
    Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After ~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every "GO" cue in order to modulate cortical activity during both the planning and execution phase of the action.

    Outcome Measures

    Primary Outcome Measures

    1. Percentage change in the time to complete the nine-hole peg test (9-HPT) to immediate post-intervention [Baseline and immediate post-intervention (up to 30 min)]

      9-hole peg test is a manual dexterity measure, estimated as the time required to complete the task (seconds)

    2. Percentage change in amplitude of motor evoked potential (MEP) to immediate post-intervention. [Baseline and immediate post-intervention (up to 60 min)]

      Motor cortical excitability is measured by electromyography using MEPs elicited by TMS

    3. Change from baseline functional connectivity to PPC stimulation target within the cortical grasping network to immediate post-intervention. [Baseline and immediate post-intervention (up to 60 min during fMRI)]

      Resting-state connectivity of low frequency BOLD fluctuations for a seed at the PPC

    4. Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in the cortical grasp network to immediate post-intervention. [Baseline and immediate post-intervention (up to 60 min during fMRI)]

      Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task

    Secondary Outcome Measures

    1. Percentage change in the time to complete the nine-hole peg test (9-HPT) to 1-week post-intervention [Baseline and 1-week post-intervention (up to 30 min)]

      9-hole peg test is a manual dexterity measure, estimated as the time required to complete the task (seconds)

    2. Percentage change in amplitude of motor evoked potential (MEP) to 1-week post-intervention. [Baseline and 1-week post-intervention (up to 60 min)]

      Motor cortical excitability is measured by electromyography using MEPs elicited by TMS

    3. Change from baseline functional connectivity to PPC stimulation target within the cortical grasping network to 1-week post-intervention. [Baseline and 1-week post-intervention (up to 60 min during fMRI)]

      Resting-state connectivity of low frequency BOLD fluctuations for a seed at the PPC

    4. Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in the cortical grasp network to 1-week post-intervention. [Baseline and 1-week post-intervention (up to 60 min during fMRI)]

      Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task

    5. Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in whole brain to immediate post-intervention. [Baseline and immediate-intervention (up to 60 min during fMRI)]

      Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task

    6. Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in whole brain to 1-week post-intervention. [Baseline and 1-week post-intervention (up to 60 min during fMRI)]

      Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task

    7. Percentage change in accuracy to precision force-tracking task to immediate post-intervention [Baseline and immediate post-intervention (up to 60 min during fMRI and outside scanner)]

      Squared distance (error) from the cursor to the target in precision force-tracking task, estimated as the root mean squared error (RMSE)

    8. Percentage change in accuracy to precision force-tracking task to 1-week post-intervention [Baseline and 1-week post-intervention (up to 60 min during fMRI and outside scanner)]

      Squared distance (error) from the cursor to the target in precision force-tracking task, estimated as the root mean squared error (RMSE)

    9. Percentage change in the mean choice reaction time to immediate post-intervention [Baseline and immediate post-intervention (up to 30 min)]

      Mean reaction time for subjects responding in the 2-choice reaction time control task, for correct responses

    10. Percentage change in the mean choice reaction time to 1-week post-intervention [Baseline and 1-week post-intervention (up to 30 min)]

      Mean reaction time for subjects responding in the 2-choice reaction time control task, for correct responses

    11. Percentage change in the normalized motor evoked potential (MEP) size to immediate post-intervention. [Baseline and immediate post-intervention (up to 60 min)]

      Parietal-motor functional connectivity is measured by electromyography using MEPs elicited by dual-site TMS, while subjects perform an object-directed grasp/subjects are at rest

    12. Percentage change in the normalized motor evoked potential (MEP) size to 1-week post-intervention. [Baseline and 1-week post-intervention (up to 60 min)]

      Parietal-motor functional connectivity is measured by electromyography using MEPs elicited by dual-site TMS, while subjects perform an object-directed grasp/subjects are at rest

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Women of child bearing age cannot be pregnant or trying to become pregnant

    • Ability to tolerate small, enclosed spaces without anxiety

    • Ability and willingness to give informed consent to participate

    • No history of neurological disorder

    • Right handed

    • English speaking

    Exclusion Criteria:
    • Are left-handed

    • Are younger than 18 or older than 50 years old

    • Women who are pregnant, suspect they are pregnant, or are attempting to become pregnant

    • Have metal anywhere in the head, excluding the mouth

    • Have a pacemaker, deep brain stimulator, vagus nerve stimulator or any other medically implanted device

    • Have cochlear hearing implants

    • Are taking GABAergic, NDMA-receptor antagonist, or other drug known to influence neural receptors

    • Have any of the below conditions that would put participants at increased risk of having a seizure: a personal or family history of seizure/epilepsy, taking prescription drugs that lower the threshold for seizures, recent history of excessive alcohol consumption, history of alcohol addiction/dependence, recent history of recreational drug use, history of drug addiction/dependence

    • Have been diagnosed with any of the following: a stroke, brain hemorrhage, brain tumor, encephalitis, multiple sclerosis, Parkinson's disease or Alzheimer's disease, depression in the past 6 months, attention deficit disorder, schizophrenia, manic depressive (bipolar) disorder, normal pressure hydrocephalus or increased intra-cranial pressure, diabetes requiring insulin treatment, any serious heart disorder or liver disease

    • Have had a migraine in the past month

    • MRI specific exclusion criteria: Any relevant history of open-heart surgery, artificial heart valve, brain aneurysm surgery, braces or extensive dental work, cataract surgery or lens implant, or artificial limb or joint. History of foreign metallic object in the body such as bullets, BB's, pellets, shrapnel, or metalwork fragments. Claustrophobia, have uncontrollable shaking, or cannot lie still for one hour.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Michigan Ann Arbor Michigan United States 48170

    Sponsors and Collaborators

    • University of Michigan
    • National Institute of Neurological Disorders and Stroke (NINDS)

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Vesia, PhD, Assistant Professor, Movement Science, University of Michigan
    ClinicalTrials.gov Identifier:
    NCT05103176
    Other Study ID Numbers:
    • HUM00186637
    • 1R21NS118055-01A1
    First Posted:
    Nov 2, 2021
    Last Update Posted:
    Mar 22, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Michael Vesia, PhD, Assistant Professor, Movement Science, University of Michigan

    Study Results

    No Results Posted as of Mar 22, 2022